В хода на клиничните изпитвания са разработени препоръки за корекция на дозата (вж.
Dose modification for all patients If severe adverse reactions or laboratory abnormalities develop during therapy with Ribavirin and peginterferon alfa-2b or interferon alfa-2b, modify the dosages of each product if appropriate, until the adverse reactions abate.